{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:08:20Z","timestamp":1782878900760,"version":"3.54.5"},"reference-count":57,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>In spite of plausible biology, the majority of oncology trials involving drug repurposing have failed to demonstrate any efficacy. Numerous factors can potentially cause failure, including issues with dosing, drug strength, the trial design itself, and patient diversity. A major, potentially correctable contributor is the absence of pharmacogenomic eligibility criteria. Here, we propose the Pharmacogenomic Stratification Framework for Drug Repurposing (PSDR), a novel framework for drug response that encompasses the triad of Exposure (E, pharmacokinetic adequacy), Target engagement (T, somatic tumor genomics), and Context competence (C, tumor microenvironment). These domains are represented as R = E \u00d7 T \u00d7 C, an eligibility model capturing the necessary, though not sufficient, conditions for anticancer drug activity. The model is not presented as an empirically validated quantitative law but as a conceptual framework to guide biomarker-stratified trial design. We derive five testable pharmacogenomic hypotheses for metformin, statins, beta-blockers, NSAIDs, and SSRIs, and propose a three-point PSDR eligibility scoring system. Prospective validation of each hypothesis in appropriately stratified cohorts is required before clinical implementation. The PSDR framework complements rather than replaces existing precision oncology resources (OncoKB, CIViC, PharmGKB, CPIC, DepMap, GDSC) by integrating germline pharmacokinetics, somatic genomics, and microenvironmental profiling for repurposed agents. If validated, PSDR-guided enrichment designs could substantially improve the efficiency and interpretability of repurposing trials. The PSDR framework should be considered a conceptual and hypothesis-generating model that requires prospective validation before clinical implementation.<\/jats:p>","DOI":"10.3390\/ph19060957","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:06:34Z","timestamp":1782875194000},"page":"957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenomic Stratification for Oncology Drug Repurposing: An Exposure Target Context Eligibility Framework"],"prefix":"10.3390","volume":"19","author":[{"given":"Mohamed","family":"El-Tanani","sequence":"first","affiliation":[{"name":"RAK College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-2820","authenticated-orcid":false,"given":"Adil Farooq","family":"Wali","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-8158","authenticated-orcid":false,"given":"Syed Arman","family":"Rabbani","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"El-Tanani","sequence":"additional","affiliation":[{"name":"Royal Cornwall Hospital Trust, National Health Service, Truro TR1 3LJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Rangraze","sequence":"additional","affiliation":[{"name":"RAK College of Medical Sciences, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frezah","family":"Muhana","sequence":"additional","affiliation":[{"name":"Princess Sarvath Community College, Amman 11196, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1158\/2159-8290.CD-21-0612","article-title":"Can drug repurposing accelerate precision oncology?","volume":"12","author":"Schipper","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3332\/ecancer.2014.485","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014Mebendazole as an anti-cancer agent","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology\u2014Patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast cancer mortality: A population-based study","volume":"29","author":"Barron","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease\u2013free survival in patients with breast cancer: The MA.32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2012.12.008","article-title":"LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin","volume":"23","author":"Shackelford","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: One name, many proteins","volume":"26","author":"Prives","year":"2012","journal-title":"Genes Dev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm1447","article-title":"Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma","volume":"12","author":"Thaker","year":"2006","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10555-011-9324-x","article-title":"Eicosanoid signalling pathways in the development and progression of colorectal cancer: Novel approaches for prevention\/intervention","volume":"30","author":"Cathcart","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djt028","article-title":"RanGTPase: A candidate for Myc-mediated cancer progression","volume":"105","author":"Yuen","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","article-title":"Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds","volume":"21","author":"Thellung","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"El-Tanani, M., Nsairat, H., Mishra, V., Mishra, Y., Aljabali, A.A.A., Serrano-Aroca, \u00c1., and Tambuwala, M.M. (2023). Ran GTPase and its importance in cellular signaling and malignant phenotype. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043065"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2337\/db14-1388","article-title":"Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS study","volume":"64","author":"Dujic","year":"2015","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenetics Genom."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1177932219899051","DOI":"10.1177\/1177932219899051","article-title":"Multi-omics data integration, interpretation, and its application","volume":"14","author":"Subramanian","year":"2020","journal-title":"Bioinform. Biol. Insights"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg3899","article-title":"High-throughput functional genomics using CRISPR-Cas9","volume":"16","author":"Shalem","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin\u2013dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/onc.2012.6","article-title":"Targeting tumor cell metabolism with statins","volume":"31","author":"Clendening","year":"2012","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenomics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Scott","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1073\/pnas.0308061100","article-title":"The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress","volume":"101","author":"Shaw","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1002\/cncr.29392","article-title":"Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer","volume":"121","author":"Watkins","year":"2015","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc3978","article-title":"Sympathetic nervous system regulation of the tumor microenvironment","volume":"15","author":"Cole","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","first-page":"779","article-title":"Treatment with \u03b2-blockers and reduced disease progression in patients with thick melanoma","volume":"171","author":"Grazzini","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature13110","article-title":"Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides","volume":"508","author":"Birsoy","year":"2014","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-14-2425","article-title":"Metabolic dependencies in RAS-driven cancers","volume":"21","author":"Kimmelman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.mayocp.2017.09.001","article-title":"Pharmacogenomics: Precision medicine and drug response","volume":"92","author":"Weinshilboum","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"McDonagh","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: Functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"djv006","DOI":"10.1093\/jnci\/djv006","article-title":"Effect of metformin vs placebo on weight and metabolic factors in NCIC CTG MA.32","volume":"107","author":"Goodwin","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2013.54.4569","article-title":"Statin use after colorectal cancer diagnosis and survival: A population-based cohort study","volume":"32","author":"Cardwell","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2002-07-2044","article-title":"Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells","volume":"101","author":"Holder","year":"2003","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","article-title":"STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data","volume":"44","author":"Szklarczyk","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41573-025-01164-x","article-title":"Computational drug repurposing: Approaches, evaluation of in silico resources and case studies","volume":"24","author":"Tanoli","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_56","unstructured":"U.S. Food and Drug Administration (2026, May 15). Enrichment Strategies for Clinical Trials to Support Demonstration of Effectiveness of Human Drugs and Biological Products: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrd3979","article-title":"Implementing personalized cancer genomics in clinical trials","volume":"12","author":"Simon","year":"2013","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:29:14Z","timestamp":1782876554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060957"],"URL":"https:\/\/doi.org\/10.3390\/ph19060957","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}